pentobarbital will reduce the extent or effect of buprenorphine buccal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

pentobarbital will reduce the level or influence of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Not known.

CYP3A4 inducers may possibly improve the metabolism of clopidogrel to its active metabolite. Watch patients for probable increase in antiplatelet effects when CYP3A4 inducers are employed together with clopidogrel

Reserve concomitant prescribing of these drugs in individuals for whom other therapy alternatives are inadequate. Restrict dosages and durations to the minimum amount required. Observe intently for indications of respiratory depression and sedation.

pentobarbital will reduce the extent or result of nicardipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.

pentobarbital will decrease the extent or influence of temsirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye here on.

Contraindicated (one)pentobarbital decreases levels of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers can decrease panobinostat ranges by ~70% and lead to treatment method failure.

pentobarbital will increase toxicity of methoxyflurane by escalating metabolism. Contraindicated. Elevated metabolism of methoxyflurane to nephrotoxic compounds.

To attenuate the possibility of overdosage or the development of dependence, Restrict the prescribing and dispensing of sedative-hypnotic barbiturates, to the amount necessary with the interval right up until the next appointment

pentobarbital will decrease the level or outcome of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Intently. Suggested atogepant dosage with concomitant utilization of sturdy or average CYP3A4 inducers is 30 mg or 60 mg qDay.

Contraindicated (1)pentobarbital will decrease the extent or influence of lorlatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will lessen the extent or result of eucalyptus by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.

With therapeutic doses of TCAs, barbiturates enhance metabolism and decrease blood concentrations of TCAs.

pentobarbital will minimize the extent or impact of alosetron by affecting hepatic enzyme CYP2C9/ten metabolism. Slight/Significance Unknown.